• HCAR3 Agonist Selectivity Revealed by Cryo-EM

  2026-08-22

  Ye et al. used cryo-EM and cAMP signaling assays to define how HCAR3 recognizes several agonists and how its binding pocket differs from HCAR2. The structures identify ligand-contact features that may guide HCAR3-focused studies of lipid metabolism while helping researchers interpret receptor selectivity and assay design.

• ZIF8 Nanotheranostics for Ultrasound-Guided TNBC Therapy

  2026-08-21

  Li et al. developed FA-PEG@ZIF8@CIP, a folate-targeted ZIF8 nanoplatform that combines ultrasound imaging, pH-responsive ciprofloxacin release, sonodynamic therapy, chemotherapy, and immune activation for triple-negative breast cancer. The study links ultrasound-triggered reactive oxygen species production with immunogenic cell death and increased CD8+ T-cell infiltration, while also identifying important translational questions about dosing, ultrasound parameters, safety, and tumor heterogeneity.

• Cyclopamine A8340 for Reliable Viability Assays

  2026-08-20

  Learn how Cyclopamine (SKU A8340) can improve experimental planning for Hedgehog pathway inhibition, viability assays, proliferation studies, and apoptosis analysis. This scenario-based guide covers dosing, DMSO compatibility, interpretation, workflow controls, and practical product-selection criteria.

• Optimized GBA1 mRNA for Gaucher Disease Therapy

  2026-08-20

  A 2026 study engineered human GBA1 mRNA by optimizing untranslated regions, codon usage, and poly(A) tails to improve glucocerebrosidase expression and persistence. The optimized mRNA restored lysosomal phenotypes in GBA1-knockout cells and produced detectable enzyme activity in mouse liver and spleen after lipid nanoparticle delivery, supporting further evaluation of mRNA therapy for Gaucher disease.

• SB-3CT for MMP9–PNN Assay Design

  2026-08-19

  SB-3CT is a selective gelatinase inhibitor for separating MMP-2 and MMP-9 activity in extracellular-matrix studies. This article translates new Adamtsl3–MMP9–perineuronal-net findings into practical assay decisions while defining what the compound can—and cannot—prove in CNS and cancer research.

• SM-102 for mRNA Delivery: Evidence and Workflow

  2026-08-19

  SM-102 is an ionizable lipid used in lipid nanoparticles for mRNA delivery, including mRNA vaccine development. Product specifications define its chemical identity, ethanol solubility, purity, and low-temperature storage requirements, while peer-reviewed evidence shows that LNP performance depends strongly on formulation composition and experimental conditions.

• Auranofin: Thioredoxin Reductase Inhibitor Guide

  2026-08-18

  Auranofin is a thioredoxin reductase inhibitor that perturbs cellular redox homeostasis and supports apoptosis-focused research. Product-reported benchmarks include an approximately 88 nM TrxR IC50, antimicrobial activity near 1.2 μM against Helicobacter pylori, and radiosensitization of murine tumor cells at 3–10 μM.

• O-GlcNAcylation in Porcine Oocyte Maturation

  2026-08-18

  The reference study identifies O-GlcNAcylation as an important regulator of porcine oocyte maturation, linking OGT activity with cytoskeletal organization, mitochondrial homeostasis, oxidative stress, and autophagy. Its findings suggest that this reversible post-translational modification helps coordinate the structural and metabolic requirements of meiotic progression, while also highlighting unanswered questions about mechanism and translational relevance.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody Guide

  2026-08-17

  Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides fluorescent detection of mouse primary antibodies in immunofluorescence, flow cytometry, and western blot workflows. It is intended for research use with mouse immunoglobulins and should not be used for diagnostic, medical, in vivo, or nonfluorescent applications.

• Carbapenemase Transmission in Enterobacter cloacae

  2026-08-17

  Chen et al. mapped carbapenemase-encoding genes in 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals, combining gene localization, conjugation, antimicrobial susceptibility testing, mobile-element analysis, and strain typing. The high transferability of plasmid-associated blaNDM-1 highlights horizontal dissemination as a major surveillance and infection-control concern.

• S-Adenosylmethionine: Assays Beyond the Methyl Donor

  2026-08-16

  Explore how S-adenosylmethionine and Ademetionine shape methyltransferase assays, from SAM concentration and substrate selectivity to translational interpretation. A MaMT4 case study provides a practical framework for designing more informative methylation experiments.

• DOPE Workflows for Nucleic Acid Delivery

  2026-08-15

  DOPE is more than a helper lipid for endosomal escape: it also provides a practical bridge to phosphatidylethanolamine rescue assays in fungal developmental biology. This workflow-focused guide covers formulation, transfection optimization, fungal lipid experiments, and troubleshooting with clear boundaries between established evidence and proposed screening conditions.

• BAPTA Calcium Chelator in Ca2+ Signaling

  2026-08-14

  BAPTA is a high-affinity calcium chelator for controlled reduction of free Ca2+ in biochemical and cell signaling studies. Its use at 10 μM attenuated nanoplastic–cadmium-associated apoptosis in Caco-2 cells, supporting calcium signaling modulation without making BAPTA a pathway-specific inhibitor.

• NF 449 for P2X1 Platelet Research

  2026-08-14

  NF 449 is a high-potency purinergic receptor antagonist for separating P2X1-driven platelet signaling from broader P2-receptor effects. This guide translates its pharmacology into practical platelet activation studies, collagen-induced aggregation assays, and carefully staged thrombosis workflows.

• Pyridostigmine, α7 Signaling, and Placental Necroptosis

  2026-08-13

  The reference study identifies placental necroptosis as a modifiable component of placental ischemia-driven preeclampsia-like pathology in rats. Its pharmacological experiments connect pyridostigmine-enhanced non-neuronal cholinergic signaling with α7 nicotinic acetylcholine receptor activity, while α-Bungarotoxin provides mechanistic evidence that this receptor is required for the protective response.

8657 records 1/578 page Next 12345 下5页 Last page